Targeting platelet-derived growth factor as a therapeutic approach in pulmonary fibrosis

Journal of Medical Investigation

Volumn 60, Issue 3-4, 2013, Pages 175-183

  Nishioka, Yasuhiko ^a   Azuma, Momoyo ^a   Kishi, Masami ^a   Aono, Yoshinori ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Fibroblast; Idiopathic pulmonary fibrosis; Platelet derived growth factor; Tyrosine kinase

Indexed keywords

BIBF1000; BLEOMYCIN; FIBROBLAST GROWTH FACTOR; FOCAL ADHESION KINASE; GROWTH FACTOR; IMATINIB; NINTEDANIB; PLATELET DERIVED GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VANADIUM PENTOXIDE; VASCULOTROPIN;

BIOLOGICAL ACTIVITY; CELL MIGRATION; CELL PROLIFERATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; FIBROBLAST; FIBROSING ALVEOLITIS; GASTROINTESTINAL STROMAL TUMOR; HUMAN; LUNG ALVEOLUS CELL TYPE 2; LUNG DEVELOPMENT; LUNG FIBROSIS; MOLECULAR MECHANICS; MOLECULAR THERAPY; MOUSE; NONHUMAN; PATHOGENESIS; PROGNOSIS; PROTEIN EXPRESSION; RAT; REVIEW; SKIN TIGHTNESS;

ANIMALS; BENZAMIDES; DISEASE MODELS, ANIMAL; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PIPERAZINES; PLATELET-DERIVED GROWTH FACTOR; PNEUMOCYTES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84887003393     PISSN: 13431420     EISSN: 13496867     Source Type: Journal    
DOI: 10.2152/jmi.60.175     Document Type: Review

References (51)

1. Gross TJ, Hunninghake GW: Idiopathic pulmonary fibrosis. N Engl J Med 345: 517-525, 2001
2. Selman M, King TE Jr, Pardo A: Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-51, 2001
3. American Thoracic Society: Idiopathic pulmonary fibrosis: Diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 161: 646-664, 2000
4. Collard HR, King TE Jr: Demystifying idiopathic interstitial pneumonia. Arch Intern Med 163: 17-29, 2003
5. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King TE Jr, Kondoh Y, Myers J, Muller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schunemann HJ: An official ATS/ERS/JRS/ ALAT statement: Idiopathic pulmonary fibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183: 788-824, 2011
6. Richeldi L, Costabel U, Selman M, Kim DS, Hansell DM, Nicholson AG, Brown KK, Flaherty KR, Noble PW, Raghu G, Brun M, Gupta A, Juhel N, Klüglich M, du Bois RM: Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365: 1079-087, 2011
7. Günther A, Korfei M, Mahavadi P, von der Beck D, Ruppert C, Markart P: Unravelling the progressive pathophysiology of idiopathic pulmonary fibrosis. Eur Respir Rev 21: 152-160, 2012
8. Noble PW, Barkauskas CE, Jiang D: Pulmonary fibrosis: patterns and perpetrators. J Clin Invest 122: 2756-2762, 2012
9. Herdin CH, Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 79: 1283-1316, 1999
10. Li X, Eriksson U: Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 14: 91-98, 2003
11. Andrae J, Gallini R, Betsholtz C: Role of platelet-derived growth factors in physiology and medicine. Genes Dev 22: 1276-1312, 2008
12. Boström H, Willetts K, Pekny M, Levéen P, Lindahl P, Hedstrand H, Pekna M, Hellström M, Gebre-Medhin S, Schalling M, Nilsson M, Kurland S, Törnell J, Heath JK, Betsholtz C: PDGF-A signaling is a critical event in lung alveolar myofibroblast development and alveo, genesis. Cell 14: 863-873, 1996
13. Soriano P: The PDGFa receptor is required for neural crest cell development and for normal patterning of the somites. Development 124: 2691-2700, 1997
14. Levéen P, Pekny M, Gebre-Medhin S, Swolin B, Larsson E, Betsholtz C: Mice deficient for PDGF B show renal, cardiovascular, and hematological abnormalities. Genes Dev 8: 1875-1887, 1994
15. Soriano P: Abnormal kidney development and hematological disorders in PDGF beta-receptor mutant mice. Genes Dev 8: 1888-1896, 1994
16. McGowan SE, Grossmann RE, Kimani PW, Holmes AJ: Platelet-derived growth factor receptor-alpha-expressing cells localize to the alveolar entry ring and have characteristics of myofibroblasts during pulmonary alveolar septal formation. Anat Rec (Hoboken) 291: 1649-1661, 2008
17. Maeda A, Hiyama K, Yamakido H, Ishioka S, Yamakido M: Increased expression of plateletderived growth factor A and insulin-like growth factor-I in BAL cells during the development of bleomycin-induced pulmonary fibrosis in mice. Chest 109: 780-786, 1996
18. Walsh J, Absher M, Kelley J: Variable expression of platelet-derived growth factor family proteins in acute lung injury. Am J Respir Cell Mol Biol 9: 637-644, 1993
19. Zhou Y, Zheng J, Laboy M, Lasky JA: Modulation of PDGF-C and PDGF-D expression during bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol 286: L182-L188, 2004
20. Shimizu S, Gabazza EC, Taguchi O, Yasui H, Taguchi Y, Hayashi T, Ido M, Shimizu T, Nakagaki T, Kobayashi H, Fukudome K, Tsuneyoshi N, D'Alessandro-Gabazza CN, Izumizaki M, Iwase M, Homma I, Adachi Y, Suzuki K: Activated protein C inhibits the expression of platelet-derived growth factor in the lung. Am J Respir Crit Care Med 167: 1416-1426, 2003
21. Yoshida M, Sakuma J, Hayashi S, Abe K, Saito I, Harada S, Sakatani M, Yamamoto S, Matsumoto N, Kaneda Y: A histologically distinctive interstitial pneumonia induced by overexpression of the interleukin 6, transforming growth factor beta 1, or platelet-derived growth factor B gene. Proc Natl Acad Sci USA 92:9570-9574, 1995
22. Antoniades HN, Bravo MA, Avila RE, Galanopoulos T, Neville-Golden J, Maxwell M, Selman M: Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 86: 1055-1064, 1990
23. Homma S, Nagaoka I, Abe H, Takahashi K, Seyama K, Nukiwa T, Kira S: Localization of platelet-derived growth factor and insulin-like growth factor I in the fibrotic lung. Am J Respir Crit Care Med 152: 2084-2089, 1995
24. Gochuico BR, Avila NA, Chow CK, Novero LJ, Wu HP, Ren P, MacDonald SD, Travis WD, Stylianou MP, Rosas IO: Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med 168: 159-166, 2008
25. Rice AB, Moomaw CR, Morgan DL, Bonner JC: Specific inhibitors of platelet-derived growth factor or epidermal growth factor receptor tyrosine kinase reduce pulmonary fibrosis in rats. Am J Pathol 55: 213-221, 1999
26. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344: 1031-1037, 2001
27. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M:ActivityofaspecificinhibitoroftheBCRABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344: 1038-1042, 2001
28. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H:Efficacyandsafetyofimatinibmesylatein advanced gastrointestinal stromal tumors. N Engl J Med 347: 472-480, 2002
29. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Silberman S, Nielsen OS: European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 358: 1421-1423, 2001
30. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB: Effects of s selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nature Med 2: 561-566, 1996
31. Aono Y, Nishioka Y, Inayama M, Ugai M, Kishi J, Uehara H, Izumi K, Sone S: Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 171: 1279-1285, 2005
32. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB: Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 114: 1308-1316, 2004
33. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Gröne HJ, Lipson KE, Huber PE: Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 201: 925-935, 2005
34. Yoshida M, Sakuma-Mochizuki J, Abe K, Arai T, Mori M, Goya S, Matsuoka H, Hayashi S, Kaneda Y, Kishimoto T: In vivo gene transfer of an extracellular domain of platelet-derived growth factor beta receptor by the HVJliposome method ameliorates bleomycin-induced pulmonary fibrosis. Biochem Biophys Res Commun 265: 503-508, 1999
35. Gilbert RE, Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic Paterson DJ: PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 59: 1324-1332, 2001
36. Wang S, Wilkes MC, Leof EB, Hirschberg R: Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 19: 1-11, 2005
37. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H: Imatinib mesylate (STI-571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 288: G907-913, 2005
38. Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J:Oralimatinibtreatmentreducesearlyfibrogenesis but does not prevent progression in the long term. J Hepatol 44: 167-75, 2006
39. Beham-Schmid C, Apfelbeck U, Sill H, Tsybrovsky O, Hofler G, Haas OA, Linkesch W:Treatmentofchronicmyelogenousleukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis. Blood 99: 381-383, 2002
40. Klion AD, Robyn JA, Akin C, Noel P, Brown MR, Law MA, Metcalfe DD, Dunbar CE, Nutman TB: Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome. Blood 103: 473-478, 2003
41. Chaudhary NI, Roth GJ, Hilberg F, MüllerQuernheim J, Prasse A, Zissel G, Schnapp A, Park JE: Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 29 (5): 976-985, 2007
42. Rhee CK, Lee SH, Yoon HK, Kim SC, Lee SY, Kwon SS, Kim YK, Kim KH, Kim TJ, Kim JW: Effect of nilotinib on bleomycin-induced acute lung injury and pulmonary fibrosis in mice. Respiration 82: 273-287, 2011
43. Chung L, Fiorentino DF, Benbarak MJ, Adler AS, Mariano MM, Paniagua RT, Milano A, Connolly MK, Ratiner BD, Wiskocil RL, Whitfield ML, Chang HY, Robinson WH: Molecular framework for response to imatinib mesylate in systemic sclerosis. Arthritis Rheum 60: 584-591, 2009
44. Sfikakis PP, Gorgoulis VG, Katsiari CG, Evangelou K, Kostopoulos C, Black CM: Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) 47: 735-737, 2008
45. Distler JH, Manger B, Spriewald BM, Schett G, Distler O: Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease. Arthritis Rheum 58: 2538-42, 2008
46. Spiera RF, Gordon JK, Mersten JN, Magro CM, Mehta M, Wildman HF, Kloiber S, Kirou KA, Lyman S, Crow MK: Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial. Ann Rheum Dis 70: 1003-1009, 2011
47. Bournia VK, Evangelou K, Sfikakis PP: Therapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinib. Semin Arthritis Rheum 42: 377-390, 2013
48. Daniels CE, Lasky JA, Limper AH, Mieras K, Gabor E, Schroeder DR: Imatinib-IPF Study Investigators: Imatinib treatment for idiopathic pulmonary fibrosis: Randomized placebo-controlled trial results. Am J Respir Crit Care Med 181(6): 604-610, 2010
49. Thannickal VJ, Roman J: Challenges in translating preclinical studies to effective drug therapies in idiopathic pulmonary fibrosis. Am J Crit Care Med 181: 532-533, 2010
50. Vuorinen K, Ohlmeier S, Leppäranta O, Salmenkivi K, Myllärniemi M, Kinnula VL: Peroxiredoxin II expression and its association with oxidative stress and cell proliferation in human idiopathic pulmonary fibrosis. J Histochem Cytochem 56: 951-959, 2008
51. Azuma M, Nishioka Y, Aono Y, Inayama M, Makino H, Kishi J, Shono M, Kinoshita K, Uehara H, Ogushi F, Izumi K, Sone S: Role of a1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice. Am J Respir Crit Care Med 176: 1243-1250, 2007